Follicular Lymphoma

Rituximab Maintenance Improved Long-Term Survival in Elderly With Follicular Lymphoma

Rituximab Maintenance Improved Long-Term Survival in Elderly With Follicular Lymphoma

By

A retrospective analysis of outcomes demonstrated the influence of rituximab maintenance after R-CHOP or R-CVP for follicular lymphoma in elderly patients.

Insurance Status Influences Overall Survival in Follicular Lymphoma

Insurance Status Influences Overall Survival in Follicular Lymphoma

By

Outcomes data demonstrated the impact of socioeconomic status and insurance coverage on outcomes for patients with follicular lymphoma by age (younger than 65 and 65 and older).

Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma

Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma

By

Although involved-field radiotherapy (IFRT) has a high level of disease control in patients with follicular lymphoma, relapse frequently occurs; therefore, researchers sought to determine if adding chemotherapy would improve progression-free survival.

Dual Inhibitor for Treating CLL/SLL, Follicular Lymphoma Granted Priority Review

Dual Inhibitor for Treating CLL/SLL, Follicular Lymphoma Granted Priority Review

By

Duvelisib, a first-in-class dual inhibitor of PI3K-delta and -gamma, was evaluated in patients with relapsed/refractory CLL/SLL and in patients with refractory indolent non-Hodgkin lymphoma.

Reduced Intensity Salvage Allo-HCT Effective for Follicular Lymphoma

Reduced Intensity Salvage Allo-HCT Effective for Follicular Lymphoma

By

Reduced intensity allogeneic hematopoietic cell transplantation (HCT) is an effective salvage treatment strategy in patients with follicular lymphoma.

Study Identifies Factors Influencing Advanced Follicular Lymphoma Outcomes

Study Identifies Factors Influencing Advanced Follicular Lymphoma Outcomes

By

Induction therapy with lenalidomide plus rituximab may result in control that is comparable to rituximab plus chemotherapy for the initial treatment.

Early relapse of follicular lymphoma may increase risk of death

Early relapse of follicular lymphoma may increase risk of death

Early relapse of follicular lymphoma could be carefully considered when making decisions about treatment for these patients.

Managing follicular lymphoma

Managing follicular lymphoma

Changes in how follicular lymphoma is managed have led to substantial improvement in prognosis and over all survival for patients with the disease.

New treatment regimens improving outcomes for follicular lymphoma

New treatment regimens improving outcomes for follicular lymphoma

Vaccines and monoclonal antibodies are promising new treatments for patients with follicular lymphoma.

Watchful waiting strategy OK in low-tumor burden follicular lymphoma

Watchful waiting strategy OK in low-tumor burden follicular lymphoma

Compared with rituximab, an initial watch-and-wait strategy is not detrimental in select patients.

Stem cell treatment does not improve overall survival in follicular lymphoma

High-dose chemotherapy combined with autologous stem cell transplantation did not improve overall survival in previously untreated adult patients with follicular lymphoma.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs